Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 461
Filter
1.
Vet Med Sci ; 10(3): e1432, 2024 05.
Article in English | MEDLINE | ID: mdl-38527006

ABSTRACT

BACKGROUND: Trichomonas gallinae is a parasite that causes canker and severe loss and death, especially in young pigeons. Metronidazole (MTZ) is the recommended drug for treating avian trichomoniasis. Due to drug resistance, non-chemical alternatives, such as medicinal plant extracts, are also considered possible therapies for this disease. OBJECTIVES: This study compares the antitrichomonal effects of MTZ with extracts of Camellia sinensis and Ziziphus vulgaris on T. gallinae in vitro. METHODS: Samples of T. gallinae were taken from infected pigeons. Multi-well plates with different concentrations (5, 10, 25, 50 and 100 µg/mL) of plant extracts were used for the in vitro study. RESULTS: The minimum inhibitory concentration (MIC) of C. sinensis extract was 25 µg/mL over 24 h, compared to 50 µg/mL for MTZ. The MIC value of the Z. vulgaris extracts was 50 µg/mL. CONCLUSIONS: The results suggest that the extracts of Z. vulgaris and C. sinensis, as potential natural agents, could have anti-avian trichomoniasis properties. This study also shows that MTZ, C. sinensis and Z. vulgaris are equally effective in preventing the growth of T. gallinae trophozoites in the culture.


Subject(s)
Camellia sinensis , Trichomonas Infections , Trichomonas , Ziziphus , Animals , Trichomonas Infections/drug therapy , Trichomonas Infections/veterinary , Antitrichomonal Agents/pharmacology , Antitrichomonal Agents/therapeutic use , Metronidazole/pharmacology , Metronidazole/therapeutic use , Columbidae
2.
Ann Parasitol ; 68(1): 151-157, 2022.
Article in English | MEDLINE | ID: mdl-35491905

ABSTRACT

In recent years, increasing attention has been paid in veterinary medicine to find novel natural resources to reduce the use of synthetic drugs, avoid side effects, and for better compliance of the animals' owners. Metronidazole has been used for many years in the treatment of birds' trichomonosis. Carvacrol is a terpenoid and several biologic activities was attributed to it. The present study developed and characterized a carvacrol nanoemulsion (NanoCAV) and investigated its antitrichomonal activity on Trichomonas gallinae, the causative agent of pigeon trichomonosis, under in vitro condition and compared it with carvacrol (CAV) and the standard antitrichomonal dug, metronidazole (MTZ). Additionally, cytotoxicity of the developed formulation to the fibroblast cell line was evaluated. The NanoCAV mean size and surface charge were 80.5 nm and -31.2 mv, respectively. No significant cytotoxicity was observed for the NanoCAV. Incorporation efficiency of NanoCAV was measured as 75%. Results of antitrichomonal activity assay showed 12 h fifty percent lethal concentrations of 0.39 and 0.27 µg/ml for CAV and NanoCAV, respectively. The NanoCAV based on in vitro activity and low cytotoxicity, can be further studied for its efficacy and safety profile in the pigeons.


Subject(s)
Bird Diseases , Trichomonas Infections , Trichomonas , Animals , Antitrichomonal Agents/pharmacology , Antitrichomonal Agents/therapeutic use , Columbidae , Cymenes , Metronidazole/pharmacology , Metronidazole/therapeutic use , Protamines , Trichomonas Infections/veterinary
3.
BMC Complement Med Ther ; 21(1): 229, 2021 Sep 13.
Article in English | MEDLINE | ID: mdl-34517859

ABSTRACT

BACKGROUND: We previously reported that the tomato glycoalkaloid tomatine inhibited the growth of Trichomonas vaginalis strain G3, Tritrichomonas foetus strain D1, and Tritrichomonas foetus-like strain C1 that cause disease in humans and farm and domesticated animals. The increasing prevalence of antibiotic resistance requires development of new tools to enhance or replace medicinal antibiotics. METHODS: Wild tomato plants were harvested and divided into leaves, stems, and fruit of different colors: green, yellow, and red. Samples were freeze dried and ground with a handheld mill. The resulting powders were evaluated for their potential anti-microbial effects on protozoan parasites, bacteria, and fungi. A concentration of 0.02% (w/v) was used for the inhibition of protozoan parasites. A high concentration of 10% (w/v) solution was tested for bacteria and fungi as an initial screen to evaluate potential anti-microbial activity and results using this high concentration limits its clinical relevance. RESULTS: Natural powders derived from various parts of tomato plants were all effective in inhibiting the growth of the three trichomonads to varying degrees. Test samples from leaves, stems, and immature 'green' tomato peels and fruit, all containing tomatine, were more effective as an inhibitor of the D1 strain than those prepared from yellow and red tomato peels which lack tomatine. Chlorogenic acid and quercetin glycosides were present in all parts of the plant and fruit, while caffeic acid was only found in the fruit peels. Any correlation between plant components and inhibition of the G3 and C1 strains was not apparent, although all the powders were variably effective. Tomato leaf was the most effective powder in all strains, and was also the highest in tomatine. S. enterica showed a minor susceptibility while B. cereus and C. albicans fungi both showed a significant growth inhibition with some of the test powders. The powders inhibited growth of the pathogens without affecting beneficial lactobacilli found in the normal flora of the vagina. CONCLUSIONS: The results suggest that powders prepared from tomato leaves, stems, and green tomato peels and to a lesser extent from peels from yellow and red tomatoes offer potential multiple health benefits against infections caused by pathogenic protozoa, bacteria, and fungi, without affecting beneficial lactobacilli that also reside in the normal flora of the vagina.


Subject(s)
Antitrichomonal Agents/pharmacology , Antitrichomonal Agents/therapeutic use , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Solanum lycopersicum/chemistry , Solanum lycopersicum/parasitology , Trichomonas Infections/drug therapy , Animals , California , Cats/parasitology , Cattle/parasitology , Female , Fruit/chemistry , Humans , Male , Plant Leaves/chemistry , Plant Stems/chemistry , Trichomonas/drug effects
4.
Parasitol Res ; 120(9): 3263-3272, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34342682

ABSTRACT

In recent years, increasing attention has been paid to the novel drug delivery systems to reduce the dose of the drug and avoid side effects. Metronidazole has been used for many years in the treatment of anaerobic bacterial and protozoal infections. Nanolactoferrin, a newly developed antibacterial agent originated from lactoferrin, is applied both as an active therapeutic and a drug nanocarrier. The present study describes the development and characterization of metronidazole-loaded lactoferrin nanoparticles (nano-MTZ) as well as reports their antitrichomonal activity on Trichomonas gallinae, the protozoal causative agent of pigeon trichomoniasis. The activity of the nano-MTZ is compared with the regular metronidazole formulation (MTZ) under in vitro and in vivo conditions. Additionally, cytotoxicity of the nano-MTZ to fibroblast cell line and possible hepatotoxicity in treated pigeons were evaluated. Nano-MTZ was prepared based on the thermal treatment method and the average size and surface charge of the dispersion were 30.6 nm and - 44.6 mv, respectively. No significant cytotoxicity was noted for the nano-MTZ in comparison to the MTZ. Loading efficiency in nano-MTZ was calculated as 55%. In vitro susceptibility results demonstrated 24 h 90% lethal concentration values of 4.23 and 6.64 µg/mL for MTZ and nano-MTZ, respectively. Oral treatment of the pigeons experimentally infected with T. gallinae resulted in the earlier eradication of the infection in the nano-MTZ-treated pigeons. No adverse effects on the liver function have been observed for the nano-MTZ. These findings suggest that nanolactoferrin is a promising platform for the development of novel MTZ formulations with improved antitrichomonal activity.


Subject(s)
Antitrichomonal Agents/therapeutic use , Columbidae/parasitology , Lactoferrin , Metronidazole/therapeutic use , Nanoparticles , Trichomonas Infections , Animals , Trichomonas Infections/drug therapy , Trichomonas Infections/veterinary
5.
Int J STD AIDS ; 32(1): 89-91, 2021 01.
Article in English | MEDLINE | ID: mdl-33121364

ABSTRACT

Metronidazole desensitization is recommended in patients with trichomoniasis and history of an allergic reaction to metronidazole due to presumed cross reactivity with tinidazole and lack of reliably safe and effective alternative therapies. We report our experiences in a patient with persistent trichomoniasis who failed to complete metronidazole desensitization due to a burning sensation over her whole body and pruritus but was later successfully desensitized to tinidazole without experiencing any adverse effects.


Subject(s)
Antitrichomonal Agents/pharmacology , Antitrichomonal Agents/therapeutic use , Metronidazole/adverse effects , Tinidazole/therapeutic use , Trichomonas Infections/drug therapy , Trichomonas vaginalis/drug effects , Adult , Drug Resistance , Female , Humans , Hypersensitivity , Treatment Outcome , Trichomonas vaginalis/isolation & purification
6.
Curr Med Sci ; 39(5): 836-842, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31612405

ABSTRACT

This study aims to analyze the clinical use of ornidazole injection at the post-marketing stage by centralized hospital monitoring system method, and investigate its widespread use in patients, in order to regulate and guide the rational drug use, improve the drug specificity and provide a basis for drug therapy. The study adopts a prospective, multi-center, large sample size, centralized hospital monitoring system. We selected five leading hospitals in Hubei province, and observed the inpatients who received the ornidazole injection from July 1, 2015 to October 31, 2015. The basic information of patients was recorded, as well as the drug use and adverse events. The statistical analysis was performed based on these data. A total of 4396 individuals were enrolled in this study, most of them were middle-aged female patients and the ornidazole injection was mainly used as prophylactic prior to surgery to prevent the infections, and surgical treatment of anaerobic infections, abdominal infections and pelvic infections. The irrational drug use existed mainly in the prescribing and administration process, including unreasonable dosing frequency, rapid intravenous drip speed and extended duration of drug use. Eleven cases of adverse reactions were collected during the monitoring, incidence rate of adverse reactions was 2.5‰; adverse drug reactions occurred within 30 min. The study results fully reflected the usage of ornidazole injection in the real world. Based on the study, we calculated the adverse reaction incidence of ornidazole and identified the risk factors which may affect the safety of ornidazole injection. Study results strongly recommend that the manufacturers should publish standards for inpatient use and doctors should prescribe with caution accordingly.


Subject(s)
Antitrichomonal Agents/therapeutic use , Drug Monitoring/trends , Medication Systems, Hospital/statistics & numerical data , Ornidazole/therapeutic use , Pre-Exposure Prophylaxis/statistics & numerical data , Product Surveillance, Postmarketing/trends , Adult , Aged , Antitrichomonal Agents/adverse effects , Antitrichomonal Agents/supply & distribution , Female , Humans , Injections , Inpatients , Male , Middle Aged , Opportunistic Infections/prevention & control , Ornidazole/adverse effects , Ornidazole/supply & distribution , Pelvic Infection/prevention & control , Practice Patterns, Physicians'/statistics & numerical data , Pre-Exposure Prophylaxis/methods , Prospective Studies , Risk Factors
8.
Turkiye Parazitol Derg ; 42(2): 168-170, 2018 Jun.
Article in English | MEDLINE | ID: mdl-30070647

ABSTRACT

We aimed to demonstrate that Pentatrichomonas hominis may also be an agent, although rare, in diarrheal episodes. Stool samples were first examined macroscopically and microscopically during routine parasitological examinations. Samples were then evaluated by Native-Lugol and formol-ethyl acetate centrifugation method. To exclude other pathogenic bacterial agents, a bacteriological culture method was applied. Samples were evaluated using a qualitative immunochromatographic test kit for rotavirus and adenovirus. We presented three cases of 77-year-old and 10-year-old male and 9-year-old female patients. Cases 1 and 2 were admitted to the hospital with complaints of diarrhea, abdominal pain, and weakness in July 2013. Leukocytes and active P. hominis trophozoites were detected. No bacterial and other parasitic and viral agents were found in their stool specimens. Oral metronidazole treatments were administered to the patients. In Case 3, P. hominis trophozoites were detected in the cellophane band in the plastic locked bag which could survive for 48 hduring a field survey in May 2012. Case 3 was contacted and advised to visit a pediatrician. P. hominis is a rare parasitic zoonosis, and we believe that it should not be ignored among diarrheal agents.


Subject(s)
Gastrointestinal Diseases/diagnosis , Trichomonas Infections/diagnosis , Trichomonas/isolation & purification , Administration, Oral , Aged , Animals , Antitrichomonal Agents/therapeutic use , Child , Diagnosis, Differential , Diarrhea/parasitology , Female , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/parasitology , Humans , Male , Metronidazole/therapeutic use , Trichomonas Infections/drug therapy , Trichomonas Infections/parasitology
10.
Int J STD AIDS ; 29(8): 825-827, 2018 07.
Article in English | MEDLINE | ID: mdl-29393008

ABSTRACT

This study presents a case report of a female patient with symptomatic refractory Trichomonas vaginalis infection who was not able to clear her infection with high-dose oral metronidazole, oral tinidazole, intra-vaginal zinc sulfate, intra-vaginal metronidazole, intra-vaginal tinidazole, and intra-vaginal boric acid. She was unable to tolerate intra-vaginal paromomycin. A combination of intravenous metronidazole, oral tinidazole liquid suspension, and intra-vaginal boric acid for 14 days subsequently achieved a complete symptomatic and laboratory cure.


Subject(s)
Antiprotozoal Agents/administration & dosage , Antitrichomonal Agents/administration & dosage , Boric Acids/administration & dosage , Metronidazole/administration & dosage , Tinidazole/administration & dosage , Trichomonas Vaginitis/drug therapy , Trichomonas vaginalis/drug effects , Administration, Intravaginal , Administration, Intravenous , Adult , Antiprotozoal Agents/therapeutic use , Antitrichomonal Agents/therapeutic use , Boric Acids/therapeutic use , Female , Gastric Bypass , Humans , Metronidazole/therapeutic use , Tinidazole/therapeutic use , Treatment Outcome , Trichomonas vaginalis/isolation & purification
13.
Rev Esp Enferm Dig ; 109(1): 64-65, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28100059

ABSTRACT

The authors present the case of a 32-year-old Caucasian male, engineer, who was submitted to a colonoscopy after a presumptive diagnosis of ulcerative colitis. The patient referred an acute bloody and mucous diarrhea, lasting for three weeks, with no fever or rectal tenesmus. Stool studies were negative. During the procedure, colonic segments with continuous hyperemic and exudative mucosa, with small papules with apical ulcers and erosions, were observed.


Subject(s)
Colitis, Ulcerative/etiology , Entamoeba histolytica , Entamoebiasis/complications , Adult , Antitrichomonal Agents/therapeutic use , Colitis, Ulcerative/psychology , Entamoebiasis/drug therapy , Entamoebiasis/parasitology , Humans , Male , Metronidazole/therapeutic use
14.
Cutan Ocul Toxicol ; 36(3): 294-296, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27780370

ABSTRACT

BACKGROUND: Fixed drug eruption (FDE) is a special variant of drug reaction seen on skin or mucous membrane, and typically recurs at the same location. Ornidazole-induced FDE cases have been reported extremely rare. CASE: The 48-year-old female patient was diagnosed for ornidazole-induced fixed drug reaction on the sole. The patient's history revealed that the lesion occurred for the third time in the last 6 months and she was administered ornidazole tablet 3 times by the gynecologist for genitourinary tract infection. CONCLUSION: This report presents a case of fixed drug reaction located at the sole induced by ornidazole use and a literature review.


Subject(s)
Antitrichomonal Agents/adverse effects , Drug Eruptions/etiology , Ornidazole/adverse effects , Antitrichomonal Agents/therapeutic use , Drug Eruptions/pathology , Female , Humans , Middle Aged , Ornidazole/therapeutic use , Skin/drug effects , Skin/pathology , Urinary Tract Infections/drug therapy
15.
Int J STD AIDS ; 27(10): 906-8, 2016 09.
Article in English | MEDLINE | ID: mdl-26384945

ABSTRACT

Trichomonas vaginalis is a sexually transmitted protozoan infection resulting in vulvo-vaginitis and altered vaginal discharge in symptomatic women. Trichomoniasis has been implicated in causing adverse pregnancy outcomes such as low birth weight and pre-term labour. Metronidazole is the recommended first-line treatment for trichomonal infection. Other nitroimidazoles, such as tinidazole, are used as alternative regimens with similar activity but at a greater expense. Treatment failure usually represents patient non-compliance or re-infection, although metronidazole resistance has previously been documented. Antimicrobial susceptibility testing for T. vaginalis is currently not available in the UK. Patients with disease unresponsive to first-line treatments pose a major challenge, as therapeutic options are limited. We present the case of a patient with presumed resistant infection during pregnancy, and the additional treatment issues that this presented.


Subject(s)
Antitrichomonal Agents/therapeutic use , Metronidazole/therapeutic use , Pregnancy Complications, Parasitic/drug therapy , Tinidazole/therapeutic use , Trichomonas Vaginitis/drug therapy , Trichomonas vaginalis/isolation & purification , Drug Resistance , Female , Humans , Pregnancy , Pregnancy Complications, Parasitic/diagnosis , Pregnancy Outcome , Treatment Outcome , Trichomonas Vaginitis/diagnosis , Trichomonas vaginalis/drug effects
16.
Cutan Ocul Toxicol ; 33(4): 337-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24938451

ABSTRACT

Baboon syndrome is a special form of systemic contact dermatitis to systemic or local administration of contact allergens. Baboon syndrome without known previous cutaneous sensitisation was also described as drug-related baboon syndrome or symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). The major drugs causing SDRIFE was beta-lactam antibiotic such as amoxicillin and ampicillin. We report a case of 16-year-old woman who developed pruritic eruptions after oral metronidazole treatment for diarrhea. She was diagnosed SDRIFE according to her clinical and histopathological findings. To our knowledge, our patient is the first case who developed SDRIFE due to metronidazole in the literature.


Subject(s)
Antitrichomonal Agents/adverse effects , Drug Eruptions/pathology , Exanthema/chemically induced , Metronidazole/adverse effects , Adolescent , Antitrichomonal Agents/therapeutic use , Buttocks/pathology , Diarrhea/complications , Diarrhea/drug therapy , Exanthema/pathology , Female , Humans , Metronidazole/therapeutic use , Skin/pathology
17.
Expert Rev Anti Infect Ther ; 12(6): 673-85, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24555561

ABSTRACT

Trichomonas vaginalis (TV) is a common sexually transmitted infection that can cause vaginitis, cervicitis and urethritis. Persistent and recurrent TV infections are frequent in women, potentially due to the lack of routine screening recommendations for this pathogen, the chronic nature of some infections, and drug resistance. Metronidazole and tinidazole are two oral drugs that are effective against trichomoniasis. There are few alternative treatment options for persons with a metronidazole allergy or treatment failure. Most TV isolates from women with treatment failures that have been analyzed for susceptibility testing in the United States have exhibited low-level metronidazole resistance, supporting the initial use of tinidazole for patients who fail metronidazole therapy. Several non-nitroimidazole drugs and other agents have demonstrated acceptable in vitro activity or cure rates in case reports for metronidazole-resistant trichomoniasis; however, clinical trials are imperative to evaluate their efficacy as alternative therapeutic regimens for this highly prevalent infection.


Subject(s)
Antitrichomonal Agents/therapeutic use , Drug Resistance , Sexually Transmitted Diseases/epidemiology , Trichomonas Vaginitis/epidemiology , Trichomonas vaginalis/physiology , Antitrichomonal Agents/pharmacology , Female , Humans , Male , Metronidazole/pharmacology , Metronidazole/therapeutic use , Recurrence , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/drug therapy , Tinidazole/pharmacology , Tinidazole/therapeutic use , Treatment Failure , Trichomonas Vaginitis/diagnosis , Trichomonas Vaginitis/drug therapy , Trichomonas vaginalis/drug effects
18.
J Parasitol ; 100(3): 360-3, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24456034

ABSTRACT

Trichomonas gallinae , the cause of avian trichomonosis, is most commonly found in the order Columbiformes. Racing pigeons are often treated preventively with nitro-imidazoles, which could result in the emergence of resistant isolates, and these isolates can be a threat to wildlife when exchanges occur. The sequence type of 16 T. gallinae isolates obtained from racing pigeons and 15 isolates from wild pigeons was determined based on the ITS1/5.8S rRNA/ITS2 region sequence. In addition, the resistance profiles of these isolates against 5 different nitro-imidazoles (metronidazole, dimetridazole, ronidazole, tinidazole, and carnidazole) were determined. Two different Trichomonas sequence types were isolated. Sequence type A isolates were recovered from racing and wild pigeons, in contrast to sequence type B, which was only isolated from wild pigeons. Isolates with sequence type B were all susceptible to the tested nitro-imidazoles, except for tinidazole resistance in 3 isolates. Resistance to the nitro-imidazoles was observed more frequently in isolates obtained from racing pigeons than from wild pigeons, with most isolates belonging to sequence type A. A higher percentage of the sequence type A isolated from racing pigeons, in comparison with those isolated from the wild pigeons, were resistant to the nitro-imidazoles and displayed higher mean lethal concentration (MLC) values. Two isolates belonging to sequence type A, 1 recovered from a racing pigeon and 1 from a wild pigeon, displayed a similar resistance pattern, suggesting a potential exchange of resistant isolates between racing pigeons and wild pigeons.


Subject(s)
Antitrichomonal Agents/pharmacology , Bird Diseases/parasitology , Columbidae/parasitology , Nitroimidazoles/pharmacology , Trichomonas Infections/veterinary , Trichomonas/drug effects , Animals , Animals, Domestic , Animals, Wild , Antitrichomonal Agents/therapeutic use , Bird Diseases/drug therapy , Bird Diseases/transmission , Crop, Avian/parasitology , DNA, Protozoan/chemistry , DNA, Ribosomal/chemistry , DNA, Ribosomal Spacer/chemistry , Disease Reservoirs/veterinary , Drug Resistance , Lethal Dose 50 , Nitroimidazoles/therapeutic use , Parasitic Sensitivity Tests/veterinary , Polymerase Chain Reaction/veterinary , RNA, Protozoan/genetics , RNA, Ribosomal, 5.8S/genetics , Trichomonas/classification , Trichomonas/genetics , Trichomonas/isolation & purification , Trichomonas Infections/drug therapy , Trichomonas Infections/parasitology , Trichomonas Infections/transmission
19.
Biomed Res Int ; 2013: 390920, 2013.
Article in English | MEDLINE | ID: mdl-24073401

ABSTRACT

In our presented research, we made an attempt to predict the 3D model for cysteine synthase (A2GMG5_TRIVA) using homology-modeling approaches. To investigate deeper into the predicted structure, we further performed a molecular dynamics simulation for 10 ns and calculated several supporting analysis for structural properties such as RMSF, radius of gyration, and the total energy calculation to support the predicted structured model of cysteine synthase. The present findings led us to conclude that the proposed model is stereochemically stable. The overall PROCHECK G factor for the homology-modeled structure was -0.04. On the basis of the virtual screening for cysteine synthase against the NCI subset II molecule, we present the molecule 1-N, 4-N-bis [3-(1H-benzimidazol-2-yl) phenyl] benzene-1,4-dicarboxamide (ZINC01690699) having the minimum energy score (-13.0 Kcal/Mol) and a log P value of 6 as a potential inhibitory molecule used to inhibit the growth of T. vaginalis infection.


Subject(s)
Antitrichomonal Agents/pharmacology , Antitrichomonal Agents/therapeutic use , Cysteine Synthase/antagonists & inhibitors , Cysteine Synthase/chemistry , Molecular Dynamics Simulation , Trichomonas Infections/drug therapy , Trichomonas/enzymology , Catalytic Domain , Cysteine Synthase/metabolism , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Hydrogen Bonding , Hydrophobic and Hydrophilic Interactions/drug effects , Ligands , Reproducibility of Results , Software , Substrate Specificity/drug effects , Thermodynamics , Trichomonas/drug effects , User-Computer Interface
20.
Ginecol Obstet Mex ; 81(5): 231-8, 2013 May.
Article in Spanish | MEDLINE | ID: mdl-23819423

ABSTRACT

BACKGROUND: In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy. OBJECTIVE: To compare the effectiveness of two combinations of three oral antimicrobial drugs in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis. MATERIAL AND METHOD: Aclinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5 mg. Patients of both groups received two tablets twice p.o. for one day. Cultures were performed to corroborate the diagnosis and then to demonstrate effectiveness of the schemes studied. For the analysis of the data we used measures of central tendency, dispersion and inferential statistics for comparison of proportions by c2 and Fisher's exact tests with a significance level of p < 0.05. RESULTS: All patient got clinical cure; however, regarding the microbiologic eradication a positive case was identified in group A, requiring rescue treatment. The compliance in both groups was of 100%. In both groups, statistical analysis did not show significant differences. Three patients in group A had mild adverse effects. Patients mean age was 33.4 +/- 5.3 years. CONCLUSIONS: Both treatments showed similar effectiveness against mixed cervical-vaginal infections. Microbiological efficacy was of 96% and 100% in group A and B, respectively, besides, scheme of group B was better tolerated.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Antitrichomonal Agents/therapeutic use , Azithromycin/therapeutic use , Clindamycin/therapeutic use , Fluconazole/therapeutic use , Mycoplasma Infections/drug therapy , Tinidazole/therapeutic use , Uterine Cervical Diseases/drug therapy , Uterine Cervical Diseases/microbiology , Vaginal Diseases/drug therapy , Vaginal Diseases/microbiology , Adult , Chlamydia Infections/drug therapy , Double-Blind Method , Drug Therapy, Combination , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...